Signify Health Expands In-Home Diagnostic and Preventive Services Offering, Introduces Spirometry Test for Detecting COPD
18 10월 2022 - 8:45PM
Business Wire
The expanded offering aims to increase access to screenings and
preventive care to address leading causes of morbidity and
mortality among Medicare members
Signify Health (NYSE: SGFY), a leading healthcare platform that
leverages advanced analytics, technology and nationwide healthcare
networks to create and power value-based payment programs, today
announced the expansion of its in-home Diagnostic and Preventive
Services offering for Medicare Advantage and Medicaid plan
members.
The offering supports the early detection, diagnosis, and
management of some of the leading causes of morbidity and mortality
among Medicare members, including chronic obstructive pulmonary
disease (COPD), peripheral arterial disease, colorectal cancer,
chronic kidney disease, diabetes, and low bone density. These
diagnostic and preventive services are performed during the Signify
Health In-Home Health Evaluation to deliver a comprehensive and
convenient care experience to patients.
“Early diagnosis and management of chronic conditions are
critical to achieving better health outcomes and reducing the total
cost of care,” said Marc Rothman, M.D., the Chief Medical Officer
of Signify Health. “At Signify, we are performing diagnostic tests
in the home to reduce barriers to timely diagnosis and treatment
decisions by individuals and their physicians.”
Signify Health’s newest Diagnostic and Preventive Services
offering is spirometry testing to detect COPD, which it began
offering in select geographies in 2022. COPD is the fourth leading
cause of death in the United States. Despite the high prevalence of
COPD, the CDC estimates that just 50 percent of people living with
the disease have been diagnosed. There is no cure for COPD, but
early diagnosis and treatment are critical to slow disease
progression and reduce the risk of mortality.
“The damage COPD causes to the lungs is irreversible and
incurable. However, too often COPD goes undiagnosed,” said Dr.
Rothman. “Signify Health clinicians are able to provide a real-time
diagnosis of COPD after a thorough assessment of a patient’s
spirometry test results, medical history, and physical
examination.”
Signify Health uses advanced analytics to identify health plan
members with gaps in care and to connect them with the appropriate
diagnostic and preventive health services. Delivering these
services in the home reduces barriers to care by providing health
plan members with convenient access to high-value care to improve
health outcomes.
About Signify Health
Signify Health is a leading healthcare platform that leverages
advanced analytics, technology, and nationwide healthcare provider
networks to create and power value-based payment programs. Our
mission is to build trusted relationships to make people healthier.
Our solutions support value-based payment programs by aligning
financial incentives around outcomes, providing tools to health
plans and healthcare organizations designed to assess and manage
risk and identify actionable opportunities for improved patient
outcomes, coordination and cost-savings. Through our platform, we
coordinate what we believe is a holistic suite of clinical, social,
and behavioral services to address an individual’s healthcare needs
and prevent adverse events that drive excess cost, all while
shifting services towards the home.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221018005334/en/
Media: Lynn Shepherd VP, Corporate
and Enterprise Communications lshepherd@signifyhealth.com
Signify Health (NYSE:SGFY)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Signify Health (NYSE:SGFY)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024